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Abstract
Background: This study aimed to review studies on willingness to pay (WTP) for prostate cancer screening.
Methods: This systematic-review was conducted based on the Preferred Reporting Items for Systematic Reviews
guidelines. By searching six-health-database, WTP studies on prostate cancer screening using contingent valuation
method published in English until March 2020 were included and those with unavailable full-text and inadequate
quality-assessment scores were excluded. Smith checklist was used for the quality assessment. Extracted WTPs were
converted to US dollar in 2018 using exchange rate parity and net present value formula to make comparison.
Factors’ effect was assessed by vote counting.
Results: Six final studies published after 2006 reported above 70% Smith checklist items needed to be considered
in contingent valuation study reports. Seven factors have positive effects on WTP. The reported WTP value varied
from 11$ to 588$ in Japan and Germany, respectively.
Conclusion: WTP for prostate cancer screening was positive among all studied men. The results of factors’ effect
assessment showed that better understanding prostate cancer risks or screening tests and factors such as age,
income, family history of cancer, hospitalization history, and educational level have positive effects. Moreover,
prostate-specific antigen history, health insurance, employment, and subject’s health assessment received less
attention.
The results’ generalization to all countries is not applicable because there are no studies for low- and middle-
income countries.
Systematic review registration: PROSPERO 2020 CRD42020172789
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Background
Prostate cancer is one of the most common cancers,
which is also known as the second most dangerous can-
cer among men [1]. It is estimated that one out of six
men at the age of 65 years old and above will develop
prostate cancer during his lifetime [2].
Prostate cancer imposes a significant economic burden
on the health system. The annual cost per every prostate
cancer including the cost of hospitalization and treat-
ment is reported to be between 106.7 and 179 million
euros in European countries, 9.862 billion dollars in the
USA, 103.1 million Canadian dollars, and 101.1 million
Australian dollar between 1993 and 1994 [3]. In most
cancers, the cost of cancer treatment gradually increases
since 12months prior to death, which then increases
sharply in the last 2 months before death [4]. Prostate
cancer is no exception and its treatment costs increase
along with the disease’s progress. In the USA in 2006,
the mean cost of diagnosing and treating prostate cancer
at the early stages of this disease was calculated as 10,612
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dollars, which reached 33,691 dollars in the last year of pa-
tients’ life [3].
Despite the rising rates of prevalence and mortality in
some developing countries, the existing evidence sug-
gests that mortality rate has declined in some high-
income countries. Accordingly, this reduction is attrib-
uted to screening, the use of other early diagnosis
methods, and improved treatment [5]. Notably, early de-
tection of cancer is considered as an important factor in
controlling the disease, reducing the cost of treatment,
and increasing the rate of survival; therefore, it is neces-
sary to highlight the significance of health education in
developing countries where people have inadequate
knowledge on the screening methods [6]. Early success-
ful detection of prostate cancer also helps in the elimin-
ation or reduction of treatment costs and money saving
via treating fewer men with advanced stages of prostate
cancer and metastasis [7].
The effectiveness of prostate cancer screening has
been investigated in different studies [8, 9]. A free of
charge screening for prostate cancer in Tyrol region of
Austria resulted the decreased rate of mortality up to
40–50% [10]. Moreover, a recent study that investigated
the screening test for prostate cancer in Europe, sug-
gested that mortality rate has relatively decreased by
early detection, despite the high rate of the prevalence of
this cancer [11].
The health care financial resources are scarce and de-
cision on allocating treatment and prevention is an ex-
cessively complex and challenging process [12]. In this
regard, determination of the costs and benefits of
screening can help in prioritization and optimal alloca-
tion. The level of participation in screening programs to
benefit estimation is also crucial. If people are not will-
ing to participate in screening programs, it would not be
possible to screen them. Also, on the other hand, peo-
ple’s high willingness to participate can lead to add-
itional contribution in financing part of the screening
costs in the form of out of pocket payments, which con-
sequently reduces the costs of implementing screening
programs for health policymakers. Through early detec-
tion, screening prevents a reduction in the quality of life
and reduces the risk of death, hence it is theoretically
expected that people would welcome screening. How-
ever, prediction is not enough to make a policy, and
quantitative evidence is needed. So, a monetary measure
is needed to assess people’s willingness to participate in
screening. As a result, using the willingness to pay
(WTP), as a monetary estimation, individual appraisal of
available programs and goods can be measured and a
quantitative estimation of their WTP for screening can
be provided [13]. Therefore, WTP can be regarded as
mental value of goods for customers, because they want
to pay such money for the good. Moreover, this helps
health system policymakers in achieving an approxima-
tion for consumers’ willingness to participate in finan-
cing preventive care services through WTP estimation.
Given the role of the stated preference studies to pro-
vide more accurate and policy relevant results, this study
aimed to investigate studies conducted on examining
men’s WTP for prostate cancer screening. Accordingly,





This systematic review was conducted in terms of the
Preferred Reporting Items for Systematic Reviews (PRIS
MA) guidelines. Various health databases including
Pubmed, Embase, Scopus, Global Health, Google Scholar,
and Web of Science were systematically searched. Also,
government reports, discussion papers, gray literature or
references of the extracted articles, and WHO database
were searched to prevent loses of important information
or further related studies. The keywords were selected
using the US National Library of Medicine’s Medical Sub-
ject Headings (Mesh), which were as follows: (“Prostate-
Specific Antigen” AND “Mass Screening” AND “Willing-
ness to pay” AND “Patient Acceptance of Health Care”).
Search strategies are shown in Additional file 1.
Inclusion and exclusion criteria
Inclusion criteria
This systematic review included those contingent valu-
ation studies that investigated men’s WTP for hypothet-
ical or specific prostate cancer screening test using
contingent valuation method (CVM) and were published
until March 2020. The language of the studies was re-
stricted to English.
Exclusion criteria
Studies using other techniques to estimate WTP, whose
full text was not available, and studies that did not ob-
tain enough score in quality assessment were excluded.
Quality assessment
The quality of the final studies was assessed using Smith
checklist [14]. This checklist proposes a guideline in
health subjects to illustrate some important points
concerning the conduct of contingent valuation (CV)
studies. In addition, it includes 34 questions in four cat-
egories as follows: CV development and context, CV sce-
nario description, CV reporting and results, CV validity,
and reliability. In order to score the study’s quality as-
sessment, completely reported questions would be
signed with “YES” and those that were not covered in
the reviewed articles would be signed with “NO.” The
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“Yes” and “No” scores are considered as “1” and “0,”
respectively.
Data analysis
After searching for resources, Endnote V.9 software was
used to organize the included studies. At first, the stud-
ies whose title and abstract did not meet the inclusion
criteria were removed. Thereafter, two reviewers (HF,
NM) read the full text of the remaining studies and ex-
tracted the key specifications designed. The collected
data were entered into independent sheets and their dif-
ferences, and any disagreement between the researchers
were investigated by Cohen’s kappa and then resolved
by a third researcher (AR). The accepted standards to in-
terpret kappa coefficient (KC) have been proposed as
follows: poor for KC ≤ 0, slight for KC = .01–.20, fair
for KC = .21–.40, moderate for KC = .41–.60, sub-
stantial for KC = .61–.80 = substantial, and almost
perfect for KC = .81–1 [15]
In order to assess the risk of bias, any disagreement
between researchers was discussed by team members.
Adjusting the values obtained from health economic
study is necessary in different study for making them
comparable [16]. In the present study, in order to com-
pare the results, WTP index obtained in different studies
was converted to US dollar value in 2018 using exchange
rate parity and net present value formula. In cases where
the year was not reported, the year of publication of the
study was used as the basis for currency conversion [13].
In order to decide on performing meta-analysis, het-
erogeneity among studies was also assessed.
Heterogeneity statistic interpreting is as follows: 25%
for low heterogeneity, 50% for medium heterogeneity,
and 75% and above for high heterogeneity [17].
Moreover, vote counting was used to identify the fac-
tors that more often affected prostate cancer screening
WTP as follows:
Different factors were identified and their effect on
WTP was also assessed. The factors were categorized by
their signs and significance including significant positive,
significant negative, or non-significant positive and non-
significant negative effects on WTP in included study
and then gave a vote to each factor. Finally, the votes
were counted and each factor that obtained at least three
votes or factors have the same sign and significance re-
sults in all the reviewed articles was considered as an af-
fecting factor on prostate cancer screening WTP.
Results
Search result
A total of 344 related studies were identified in the ini-
tial search (Fig. 1). There was no disagreement in search
process. 327 duplicate or irrelevant articles were re-
moved, and 18 related articles were then entered into
the next stage for performing more evaluation. Also, 12
studies were excluded due to following results: their full
text was not available (3), they did not meet the inclu-
sion criteria (7), and they reported inadequate or in-
appropriate information (2). Finally, six articles were
included in this study and then reviewed.
Agreement between interviewers (HF, NM) was per-
fect. The Cohen’s kappa coefficient in selection studies
was 0.85 (Additional file 3). Also, according to accepted
standards to interpret kappa, agreement was perfect. To-
tally, there were two disagreements between the two re-
viewers, which were resolved by the third reviewer (AZ).
Quality assessment result
The final studies were scored based on the Smith check-
list items, and the percentage of scores obtained was cal-
culated. Results are summarized in Table 1, showing
that the scores of four studies [19–22] were above 75%.
The other articles’ scores were between 65% and 74%.
It is noticeable that although the scores were accept-
able in quality evaluation, the items of “Payment vehicle”
and “Time period for” received less attention in final
studies. The items of “Transformation of value options
from one context/time to another,” “Price year,” “Time
period used in analysis,” and “Cost of intervention” were
not provided in any of the included studies. While to
have the best estimation of WTP, this item needs to be
provided.
Characteristics of the selected included studies
The assessment shown in Table 2 indicated that all the
finally selected studies were published in the last 14
years (2006 and beyond), which were conducted in de-
veloped countries [18–23]. Summary of the question-
naires or scenarios were reported in all of the studies.1
Accordingly, some studies [18, 19, 21–23] used double-
bounded dichotomous-choice approach and one of them
[20] used payment card technique for the estimation of
WTP. Five studies used prostate-specific antigen test in
their scenarios, except one study that used hypothetical
testing [23]. Populations in all of studies were men with-
out symptoms and signs of cancer except one study [18]
that was performed on prostate cancer patients. Partici-
pants’ response rate was reported in all the studies,
which was ranged from 33% [19] to 96% [23]. Respon-
dents replied through online and computer-based ques-
tionnaires in all the studies. Different factors affecting
on WTP have been examined in the studies including
demographic factors, level of income, level of education,
a history of testing, a family history of prostate cancer,
history of any disease, and some other factors. Some
1Considering the length of scenarios; they are given in Additional file 2
instead of placing them in the data extraction table.
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studies [19, 21, 22] have also examined the effect of add-
itional information such as information on screening
test, its side effects, and prostate cancer risks, as the
main subject, on WTP results. The results are summa-
rized in Table 3.
WTP for prostate screening test
In the assessment of the extracted WTP statics, studies
have shown a different range of mean value of WTP that
they were not comparable because of differences of cur-
rencies among different studied countries. Comparing
them was possible after converting in specific discount.
Because the last study was for 2018, all studied WTP
were converted to US dollar value in 2018 and dis-
counted at discount rate 3% by net present value for-
mula. Figure 2 presents WTP for prostate cancer
screening. As shown, the highest value, i.e., $ 588, was
reported in Germany and the lowest value, i.e., $ 11.3,
was reported in Japan [19].
Studies’ heterogeneity
Heterogeneity is an important challenge in WTP litera-
ture [24]. This review had some criteria that made a high
heterogeneity including type of information in scenarios,
number of scenarios, using model for estimation, type of
screening test, type and number of factors investigated
in scenarios, type of study population and sample size,
and methods for estimating CVM that are summarized
in Table 2.
Furthermore, heterogeneity in effect size was assessed
by use of statistic heterogeneity (I2). The I2 statistic de-
scribes the percentage of variations across studies that
were due to heterogeneity, rather than chance [25].
Calculations showed that in df = 5, Q = 548.994, (P
< 0.00001), I2 static equals to 99% (Additional file 3).
These results show the presence of a high heterogen-
eity, and in this situation, conclusions of a meta-
analysis are compromised; therefore, meta-analysis
was not performed.
Fig. 1 PRISMA flow diagram for study selection
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Table 1 The quality of methodology of studies
Checklist of what should be reported













CV development and context
Country where the CV survey has
been conducted and health care
financing details
Yes Yes Yes Yes Yes Yes
Focus—methodological or policy Yes Yes Yes Yes Yes Yes
Specificity of questionnaire (part of
wider survey)
Yes Yes Yes Yes Yes Yes
Details of other measures of QoL
incorporated
No Yes Yes Yes Yes No
Scenario development Yes Yes Yes Yes Yes Yes
Welfare measure (WTP or WTA) Yes Yes Yes Yes Yes Yes
CV scenario description
Intervention(s) Yes Yes Yes Yes Yes Yes
Partiality (single good or close
substitutes)
Yes Yes Yes Yes Yes Yes
Outcomes (health status, probability,
and time)
Yes Yes Yes Yes Yes Yes
Non-outcomes (information, care, other) Yes Yes Yes Yes Yes Yes
Payment vehicle Yes No No No Yes No
Presentation of uncertainty/risk Yes Yes Yes Yes Yes No
Survey period No Yes Yes Yes Yes Yes
Time period for WTP No No No No No No
Question/elicitation format Yes Yes Yes Yes Yes Yes
CV reporting and results
Method of data collection Yes Yes Yes Yes Yes Yes
Type of respondent Yes Yes Yes Yes Yes Yes
Sample size Yes Yes Yes Yes Yes Yes
Response rate Yes Yes Yes Yes Yes Yes
Type of outcomes incorporated
(use, option, or externality value)
Yes Yes Yes Yes No Yes
Duration of interview/length
of questionnaire
No Yes Yes Yes Yes Yes
WTP values (results of the studies) Yes Yes Yes Yes Yes Yes
Transformation of values from
one context/time to another
No No No No No No
Price year No No No No No No
Currency Yes Yes Yes Yes Yes Yes
Cost of intervention No No No No No No
Cost–benefit ratio No No No No No No
Time period used in analysis No No No No No No
CV validity and reliability
Tests for bias—order effect,
starting point, range, interviewer,
strategic
Yes Yes Yes Yes Yes No
Statistical analysis performed Yes Yes Yes Yes Yes Yes
Assessment of zero/high bids Yes No Yes Yes Yes Yes
Distributional issues consider Yes Yes Yes Yes No Yes
Validity tests Yes Yes Yes Yes Yes No
Reliability tests Yes Yes Yes Yes Yes No
Rate of responses 74% 76% 79% 79% 76% 65%
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Factors affecting WTP for prostate cancer screening
Characteristics
Understanding the affecting factors on WTP for prostate
cancer screening is important in financing mass screen-
ing policies and for future research design.
Different factors affecting on WTP and their signifi-
cance were examined in all the final studies. Age and in-
come were the most frequently investigated factors
reported among the studies [18–23]. Different models
were used in the final studies to estimate WTP and
assessing factor affecting on them, including logistic re-
gression [18, 23], Weibull regression analysis [19, 21],
categorical regression analysis [20], multiple regression
[22], and maximum likelihood regression [23]. There
was no limitation in the selection of the used model.
Some studies [18, 22] examined a wider range of fac-
tors affecting WTP, and the other studies examined a
limited number of factors affecting WTP. It seems that
there is not a unique producer about the included fac-
tors affecting on WTP.
Vote counting
The sign of affecting factors was not the same in all the
studies. Due to the incompatibility of the coefficients in
different studies, vote counting was used to conclude
about the factors affecting prostate cancer screening WTP
(Table 4). The factors affecting on WTP were specified
and the results show that age (5 to 0)2, income (6 to 0),
and type of information (3 to 0) were the most influencing
factors on WTP, so that their effects were proven, respect-
ively. In addition, some factors including educational level,
family history of cancer, hospitalization history, and can-
cer risk have significant effects (2 to 0), because they have
the same sign and significance results in all the reviewed
articles. The significant effect was not proven for the other
factors.
Discussion
From an ethical point of view, there is no barrier to in-
volve patients in important decisions on providing care
services for them; rather, it is a way to improve the qual-
ity of services and to “prevent unnecessary and costly
medical interventions” [26]. This research has systemat-
ically reviewed all studies that investigated WTP for
prostate cancer screening. The results of six selected
studies showed that WTP for prostate cancer screening
among men was always positive and its value was higher
in some countries such as Germany and the USA [18,
23], while it was lower in Japan [19].
Furthermore, the reviews of these studies that have ex-
amined the effect of information on WTP showed that
information have a positive and significant effect [18, 21,
22]. So, obtaining more information on screening test
such as its side effects and prostate cancer risk did not
almost reduce people’s WTP, even in cases with a nega-
tive impact [19, 21] on the WTP; it was non-significant
and WTP’s value did not reach zero. Generally, men’s
preference was screening and paying for it.
Age is the main affecting factor with the proven posi-
tive effect. As shown that prostate cancer is an aging
cancer, men’s willingness is to pay attention to rise with
aging.
Also, income and having a good financial status were
identified as positive factors affecting WTP for prostate
cancer screening in all the included studies. Having a
high income make a high WTP, hence in designing
screening programs, policymakers could consider this
issue and provide different screening packages to differ-
ent income deciles.
Experiencing any disease or being at the risk of
prostate cancer, as well as a family history of pros-
tate cancer [18, 19, 22] and history of hospitalization
[20, 21] have positive and significant effects on WTP
and motivates patients’ relatives and family members
to undergo prostate cancer tests. In other word, ex-
periencing a disease encourages men’s doing some-
thing that keeps them away from risk. It shows that
people are in search of peace of mind and they are
willing to pay for it when they are under stress con-
dition due to family members’ involvement in pros-
tate cancer.
Educational level was also identified as a positive
factor on WTP [18, 23]. The results show that men’s
with a higher educational level have higher willing-
ness to pay for prostate cancer screening. Higher level
of education may make better understanding of health
care importance on the quality of life or may be men
have more complete information on the devastating
effects of the disease because of the higher level of
study.
The effect of history of PSA test in two studies [21, 22]
was not consistent. Generalization of the results and con-
clusion about it were not possible because the assessed
studies were not sufficient. So, the inconsistency between
the results needs to be further investigated in future stud-
ies before generalizing the results.
There was not enough evidence on the other factors
including health insurance, employment, and subject as-
sessment of health to conclude, and extra research is
needed to decide about their effects on WTP.
Furthermore, it became obvious that the effect of dif-
ferences between patient and healthy men on WTP have
not been analyzed, so far. It can be considered as an im-
portant reason of different WTP values between these
studies.
25 is the number of studied positive and significant effects and 0 the
number of negative and significant effect.
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Generalizing the result to all countries is not applic-
able, because all studies were performed in developed
countries and no studies were found for low- and
middle-income countries. Therefore, it is necessary for
developing countries to design new studies with their
special features.
All the reviewed studies used the Internet and web-
based methods to send and complete their question-
naires. It seems that using face-to-face methods to col-
lect data increases the reliability of study results.
An important advantage of this study was the quality
assessment of the final studies. Although the final stud-
ies had acceptable scores in qualitative evaluation, this
assessment showed that in designing scenarios of WTP,
the factors related to “payment vehicle” and “time
period” in smith checklist have been less considered.
While the type of payment or financing for prostate can-
cer screening and periods of repeating the tests can have
effects on WTP, which are necessary to be considered in
the future studies’ scenario designing.
Although the number of studies entered into final ana-
lysis was small, but it is possible to make valid conclusions
on some of affecting factors and to set a reasonable inter-
val for WTP. However, this review had heterogeneity in
some factors including type and numbers of scenarios, the
used model of estimation, information varieties in scenar-
ios, sample size, and type of population (healthy subjects
and prostate cancer patients). Assessing effect size hetero-
geneity showed a high heterogeneity between the included
studies. Because in a high heterogeneity, the conclusions
of a meta-analysis are compromised, and meta-analysis
was not performed in this review. So, vote counting was
used to assess the affecting factors.
Conclusion
Given the growing trend of cancer patients and the re-
lated treatment costs, the health systems must seriously
consider the utilization of early detection and screening
methods, to identify people with cancer in a timely man-
ner for the purpose of reducing the related costs. The
results of this study indicated the positive WTP for pros-
tate cancer screening among all the studied men. In
addition, the assessment of factors affecting the WTP
showed that obtaining more information on screening
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1Given the different WTPs was reported in this study, we used the highest
reported WTP in our analysis
Fig. 2 The WTP for prostate cancer screening in USD
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test and prostate cancer risk make a higher WTP. The
effect of age on WTP is positive and men would have a
higher WTP in older age. Furthermore, education, his-
tory of cancer, and history of hospitalization have posi-
tive and significant effects on WTP.
Also, the positive and significant effect of income was
proven in all studies. So, policymaker can use it as a
main option to provide different screening package for
different income deciles in designing screening program.
The impacts of a health insurance, employment, subject
assessment of health, and history of PSA screening have
received less attention, and there were no fully known
effects for them.
All the reviewed studies used the Internet and
web-based methods to send and complete their
questionnaires. It seems that using face-to-face
methods to collect data increases the reliability of
study results.
Generalizing the result to all countries is not applic-
able, because there are no studies for low- and
middle-income countries. Therefore, to determine the
value of prostate cancer screening, besides the
utilization of the results of the reviewed studies, it is
necessary to conduct further research in low- and
middle-income countries.
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